Payer / HTA meeting · Dr. Daniel Tanaka

• Comparator checkpoint monotherapy

• PD-L1 testing pathway infographic
• VOYAGE-1 pivotal data summary

1. What was the median PD-L1 testing turnaround in the pivotal trial sites?
2. Is there subgroup data for patients with untreated brain metastases?

Payer / HTA meeting with thoracic medical oncologist at Policlinico Gemelli. Discussed comparator checkpoint monotherapy.